JP2005517412A - 腎疾患の診断及び治療のためのＡｘｌ受容体の使用 - Google Patents

腎疾患の診断及び治療のためのＡｘｌ受容体の使用 Download PDF

Info

Publication number
JP2005517412A
JP2005517412A JP2003568094A JP2003568094A JP2005517412A JP 2005517412 A JP2005517412 A JP 2005517412A JP 2003568094 A JP2003568094 A JP 2003568094A JP 2003568094 A JP2003568094 A JP 2003568094A JP 2005517412 A JP2005517412 A JP 2005517412A
Authority
JP
Japan
Prior art keywords
axl
activity
compound
cell
axl receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003568094A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005517412A5 (enExample
Inventor
モア、オルナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quark Pharmaceuticals Inc
Original Assignee
Quark Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quark Pharmaceuticals Inc filed Critical Quark Pharmaceuticals Inc
Publication of JP2005517412A publication Critical patent/JP2005517412A/ja
Publication of JP2005517412A5 publication Critical patent/JP2005517412A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2003568094A 2002-02-12 2003-02-12 腎疾患の診断及び治療のためのＡｘｌ受容体の使用 Pending JP2005517412A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35637402P 2002-02-12 2002-02-12
PCT/US2003/004186 WO2003068983A1 (en) 2002-02-12 2003-02-12 Use of the axl receptor for diagnosis and treatment of renal disease

Publications (2)

Publication Number Publication Date
JP2005517412A true JP2005517412A (ja) 2005-06-16
JP2005517412A5 JP2005517412A5 (enExample) 2006-04-13

Family

ID=27734638

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003568094A Pending JP2005517412A (ja) 2002-02-12 2003-02-12 腎疾患の診断及び治療のためのＡｘｌ受容体の使用

Country Status (7)

Country Link
US (3) US20030157573A1 (enExample)
EP (1) EP1483400A4 (enExample)
JP (1) JP2005517412A (enExample)
CN (1) CN1646695A (enExample)
AU (1) AU2003223172A1 (enExample)
IL (1) IL163547A0 (enExample)
WO (1) WO2003068983A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013115280A1 (ja) 2012-01-31 2013-08-08 第一三共株式会社 ピリドン誘導体
JP2016539138A (ja) * 2013-12-02 2016-12-15 ベルゲンビオ アーエス キナーゼ阻害剤の用途

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003223172A1 (en) * 2002-02-12 2003-09-04 Quark Biotech, Inc. Use of the axl receptor for diagnosis and treatment of renal disease
EP1563094A4 (en) * 2002-10-29 2007-04-25 Rigel Pharmaceuticals Inc MODULATORS OF ANGIOGENESIS AND TUMORIGENESIS
CA2561073C (en) 2004-03-27 2014-01-14 The Arizona Board Of Regents On Behalf Of The University Of Arizona Composition and method for cancer treatment
TW200726845A (en) * 2006-01-02 2007-07-16 Nat Defense Medical Ct Biomarker molecular of renal illness and detecting method for the same
CA2710051C (en) 2006-12-29 2017-05-16 Rigel Pharmaceuticals, Inc. Substituted triazoles useful as axl inhibitors
EP2170395A1 (en) * 2007-07-02 2010-04-07 Wyeth LLC Modulators of axl for use in treating bone disorders
US9074192B2 (en) 2010-01-22 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
CA3056999A1 (en) 2010-01-22 2011-07-28 Amato J. Giaccia Inhibition of axl signaling in anti-metastatic therapy
US9879061B2 (en) 2011-12-15 2018-01-30 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
EP2626705A1 (en) * 2012-02-13 2013-08-14 Institut d'Investigacions Biomédiques August Pi i Sunyer Use of the soluble form of AXL in the diagnosis and/or prognosis of heart failure syndrome
CA2909669C (en) 2014-10-20 2023-12-12 Ruga Corporation Antiviral activity of gas6 inhibitor
EA201790696A1 (ru) * 2014-10-20 2017-10-31 Астьют Медикал, Инк. Способы и композиции для диагностики и прогнозирования повреждения почек и почечной недостаточности
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
US11353465B2 (en) 2017-01-12 2022-06-07 Astute Medical, Inc. Methods and compositions for evaluation and treatment of renal injury and renal failure based on C—C motif chemokine ligand 14 measurement
WO2018193102A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
CN113215157B (zh) * 2021-05-20 2022-06-21 徐州医科大学 特异性靶向人AXL基因的sgRNA及其应用
CN113252911B (zh) * 2021-07-02 2021-12-10 珠海丽珠试剂股份有限公司 SARS-CoV-2中和抗体的检测试剂盒及其应用
KR102763266B1 (ko) * 2021-11-30 2025-02-04 충남대학교산학협력단 Axl을 포함하는 지방간 예방 또는 치료용 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468634A (en) * 1991-06-24 1995-11-21 The University Of North Carolina At Chapel Hill Axl oncogene
CA2175893C (en) * 1993-11-23 2010-06-22 Paul J. Godowski Protein tyrosine kinases named rse
WO1995019570A1 (en) * 1994-01-14 1995-07-20 Genentech, Inc. Antagonists to insulin receptor tyrosine kinase inhibitor
US5538861A (en) * 1994-07-29 1996-07-23 Amgen Inc. DNA encoding a stimulating factor for the axl receptor
US6211142B1 (en) * 1995-03-10 2001-04-03 Genentech, Inc. Compositions comprising gas6 polypeptides and articles of manufacture comprising the same
US5849585A (en) * 1995-05-10 1998-12-15 Genetech, Inc. Isolating and culturing Schwann cells
US20040102389A1 (en) * 1995-10-26 2004-05-27 Ribozyme Pharmaceuticals, Inc. Nucleic acid-mediated treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
US6235769B1 (en) * 1997-07-03 2001-05-22 Sugen, Inc. Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
US6236769B1 (en) * 1998-01-28 2001-05-22 Cognex Corporation Machine vision systems and methods for morphological transformation of an image with zero or other uniform offsets
US20030149113A1 (en) * 2001-10-12 2003-08-07 Caplan Michael J. Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
CN100523215C (zh) * 2000-12-01 2009-08-05 马普科技促进协会 介导rna干涉的小rna分子
US20020165158A1 (en) * 2001-03-27 2002-11-07 King George L. Methods of modulating angiogenesis
JP2005527639A (ja) * 2001-11-02 2005-09-15 インサート セラピューティクス インコーポレイテッド Ｒｎａ干渉の治療的利用のための方法及び組成物
AU2003223172A1 (en) * 2002-02-12 2003-09-04 Quark Biotech, Inc. Use of the axl receptor for diagnosis and treatment of renal disease
US20030229906A1 (en) * 2002-04-15 2003-12-11 Gelman Irwin H. Methods and compositions for the treatment of disorders of HIV infection
JP2007524349A (ja) * 2003-01-16 2007-08-30 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア ＩＣＡＭ−１のｓｉＲＮＡ阻害のための組成物及び方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013115280A1 (ja) 2012-01-31 2013-08-08 第一三共株式会社 ピリドン誘導体
JP2016539138A (ja) * 2013-12-02 2016-12-15 ベルゲンビオ アーエス キナーゼ阻害剤の用途

Also Published As

Publication number Publication date
WO2003068983A1 (en) 2003-08-21
AU2003223172A1 (en) 2003-09-04
US20090075923A1 (en) 2009-03-19
WO2003068983A9 (en) 2004-12-29
US20090042826A1 (en) 2009-02-12
US20030157573A1 (en) 2003-08-21
CN1646695A (zh) 2005-07-27
EP1483400A4 (en) 2007-07-11
EP1483400A1 (en) 2004-12-08
IL163547A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
US20090042826A1 (en) Use of the AXL receptor for diagnosis and treatment of renal disease
Cao et al. Neuropilin-2 promotes extravasation and metastasis by interacting with endothelial α5 integrin
DeWire et al. β-arrestin-mediated signaling regulates protein synthesis
US11035003B2 (en) TRPC6 involved in glomerulonephritis
BRPI0807205A2 (pt) Moduladores de ligantes esclerostina para tratamento de distúrbios relacionados ao osso
KR100553300B1 (ko) 혈관신생 및 심혈관형성의 촉진 또는 억제 방법
Wang et al. Interactions between extracellular signal-regulated protein kinase 1, 14-3-3ϵ, and heat shock factor 1 during stress
Hornigold et al. Inhibition of collagen I accumulation reduces glomerulosclerosis by a Hic-5-dependent mechanism in experimental diabetic nephropathy
US20090202566A1 (en) Use of the ENDO-180 gene and polypeptide for diagnosis and treatment
US20030166017A1 (en) Compositions and methods for the identification, assessment, prevention and therapy of cardiovascular disease
JP2009539842A (ja) 副甲状腺関連障害の処置におけるＴＧＦ−βアンタゴニストの使用
Zhu et al. Integrin alpha 7 interacts with high temperature requirement A2 (HtrA2) to induce prostate cancer cell death
US20050214219A1 (en) 24p3 receptors and uses thereof
CA2436661A1 (en) Novel nucleic acid and polypeptide molecules
JP2005112812A (ja) リン酸化部位特異的抗体及びそれを用いたスクリーニング方法
US20080124317A1 (en) Diagnos and Treatment of Fibrosis Related Pathology
US20040259136A1 (en) Protein kinase C zeta as a drug target for arthritis and other inflammatory diseases
JP2009535033A (ja) Ｃｒｉｐｔｏ−３の検出のための組成物および方法
JP4772684B2 (ja) スクリーニング方法
AU2003279771B2 (en) Methods for controlling proliferation of cells
CA2801162A1 (en) Diagnostic, screening and therapeutic applications of ocab-based tools
US20080095779A1 (en) Runx2 Isoforms in Angiogenesis
JP2009060787A (ja) Ｒｅｃ１６８を介する肥満細胞の脱顆粒反応を抑制する物質のスクリーニング方法及び同定方法、並びにＲｅｃ１６８アンタゴニストを含有してなる肥満細胞が関与する炎症性疾患の治療剤
US8110348B2 (en) Methods and compositions for the diagnosis and treatment of schizophrenia
Cowley et al. Neuropilin-2 Promotes Extravasation and Metastasis by Interacting with Endothelial a5 Integrin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090630